Condition: Diabetes · Diabetes Mellitus, Type II · Sponsor: Seoul National University Bundang Hospital
This multicenter, open-label, prospective study randomized 46 drug-naïve adults with T2D (HbA1c 6.5%-10.0%) to receive empagliflozin (10 mg/day) or metformin (1,000 mg/day) for 12 weeks.
This description comes directly from the study's public registry record.
Ji Young Byun Administrative staff, MS · 82-31-787-7035 · 65423@snubh.org
Always discuss trial participation with your own doctor first.
| SNUBH | Seongnam, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06846411